Table 1.
Baseline Demographic and Clinical Characteristics of Patients by Treatment After Multiple Imputation
| Fidaxomicin (n = 38) | Vancomycin (n = 200) | P Value | |
|---|---|---|---|
| Age, ya | 62.9 (56.7–74.1) | 62.5 (53.4–70.7) | .36 |
| Male | 10 (26.2) | 103 (51.5) | <.01 |
| White | 31 (80.5) | 148 (74.1) | .42 |
| Hispanic | 3 (8.4) | 11 (5.3) | .49 |
| Type of immunosuppression | .29 | ||
| Solid organ transplant | 19 (50) | 57 (28.5) | |
| Bone marrow transplant | 5 (13.2) | 19 (9.5) | |
| Leukemia/lymphoma | 5 (13.2) | 43 (21.5) | |
| Solid tumor | 4 (10.5) | 40 (20.0) | |
| Immunomodulatorb | 5 (13.2) | 41 (20.5) | |
| CCIa | 5 (3,7) | 5 (3,8) | .50 |
| Dialysis | 7 (18.4) | 16 (8.0) | .07 |
| CDI in past 6 mo | 2 (5.3) | 2 (1.2) | .09 |
| Any history of CDI | 7 (18.4) | 22 (11.0) | .23 |
| Gastric acid suppression | 30 (78.9) | 111 (55.4) | <.01 |
| Location prior to diagnosis | .03 | ||
| Hospital acquired | 20 (53.4) | 82 (41.1) | |
| Health care associated | 14 (37.1) | 56 (27.9) | |
| Community acquired | 4 (9.5) | 62 (31.1) | |
| CDI test type | .45 | ||
| Toxin and antigen assay | 20 (51.3) | 116 (58.2) | |
| NAAT (toxin gene) | 18 (49.7) | 84 (41.8) | |
| WBC counta | 6900.0 (4950–12 200) | 7600.0 (3900–12 775) | .96 |
| Severe CDI | 16 (42.4) | 75 (37.7) | .59 |
| ICU stay | 8 (19.7) | 37 (18.4) | .84 |
| Antecedent antibiotic use | 30 (77.9) | 146 (73.0) | .55 |
| No. of antecedent antibioticsa | 2 (1,3) | 1 (0,2) | .07 |
| Antibiotics during treatment | 18 (47.4) | 105 (52.5) | .60 |
| Loss to follow-up | 5 (13.2) | 35 (17.5) | .64 |
| Time to loss of follow-upa,c | 23.5 (10.5–35) | 15.5 (6–30) | .39 |
Data are presented as median (IQR) or No. (%). Chi-square was used for all testing unless otherwise specified.
Abbreviations: CCI, Charlson Comorbidity Index; CDI, Clostridioides difficile infection; ICU, intensive care unit; WBC, white blood cell count.
aMann-Whitney U test.
bImmunomodulators: infliximab, azathioprine, tocilizumab, basiliximab, 6-mercaptopurine, cyclophosphamide, cyclosporine, imatinib, high-dose steroid, adalimumab, ixekizumab, vedolizumab, leflunomide, nivolumab, sorafenib, tofacitinib.
cOnly for patients who were lost to follow-up.